Health
globalreutersOctober 11, 20241 Mins read
Aiming to Outdo Rivals in Severe Asthma, Upstream Bio Upsizes IPO to $225M
globalreutersOctober 11, 20241 Mins read 
Upstream Bio will use its IPO haul to continue clinical testing of verekitug, which it contends be a better treatment option for severe asthma compared to a commercialized Amgen and AstraZeneca drug. CAMP4 Therapeutics and Ceribell also priced IPOs to join the public markets.
The post Aiming to Outdo Rivals in Severe Asthma, Upstream Bio Upsizes IPO to $225M appeared first on MedCity News.
Related Articles
Kura Oncology Gets $330M to Kick Off Global Leukemia Drug Pact With Kyowa Kirin
Kura Oncology already had a broad development plan for ziftomenib in leukemias,...
How Much More Would People Pay in Premiums if the ACA’s Enhanced Subsidies Expired?
Enhanced Affordable Care Act (ACA) subsidies lower premium payments for ACA Marketplace...
Everything You Need to Know About Hip Replacement Surgery in India
Hip replacement surgery is one of the most common and successful medical...
Speculation on RFK Jr. as HHS Secretary
From Tyler Cowen at Marginal Revolution: One of the problems with an...
Leave a comment